Literature DB >> 20472853

Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.

Meredith A Lakey1, Animesh Pardanani, James D Hoyer, Phuong L Nguyen, Terra L Lasho, Ayalew Tefferi, Curtis A Hanson.   

Abstract

The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2(V617F) (exon 14) mutation is found in 95% of PV cases. Functionally similar mutations in JAK2 exon 12 have also been described, but a thorough bone marrow study has not been done. We identified 7 PV cases with exon 12 mutations; all had hypercellular bone marrow with erythroid hyperplasia. Small, atypical megakaryocytes predominated; atypical megakaryocyte lobation and abnormal chromatin distribution was identified in all cases. Rare clusters of megakaryocytes could be found but were typically subtle. Because JAK2 exon 12-positive PV cases lack the classic myeloproliferative morphologic features, bone marrow samples from the patients may be difficult to classify as myeloproliferative neoplasms. Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone marrow findings of erythroid hyperplasia and subtle megakaryocytic atypia, should prompt an evaluation for an exon 12 mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472853     DOI: 10.1309/AJCP3Z2AKUWRGTNM

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Authors:  Jan Jacques Michiels; Mihaela Tevet; Adrian Trifa; Emilia Niculescu-Mizil; Anca Lupu; Ana Maria Vladareanu; Horia Bumbea; Anca Ilea; Camelia Dobrea; Daniela Georgescu; Oana Patrinoiu; Mihaela Popescu; Meilin Murat; Cornel Dragan; Felicia Mihai; Sabina Zurac; Silvana Angelescu; Anamaria Iova; Alina Popa; Rodica Gogulescu; Violeta Popov
Journal:  Maedica (Bucur)       Date:  2016-03

2.  Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera.

Authors:  Shrinidhi Nathany; Sindhura Lakshmi Koulmane Laxminarayana; Siddharth Tewari; Sushma Belurkar; Ruchee Khanna; Chethan Manohar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

3.  Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Authors:  Roongrudee Singdong; Teerapong Siriboonpiputtana; Takol Chareonsirisuthigul; Adcharee Kongruang; Nittaya Limsuwanachot; Tanasan Sirirat; Suporn Chuncharunee; Budsaba Rerkamnuaychoke
Journal:  Asian Pac J Cancer Prev       Date:  2016-10-01

4.  Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.

Authors:  Afia Muhammad Akram; Humera Kausar; Asma Chaudhary; Ahmad Mukhtar Khalid; Muhammad Mudassar Shahzad; Muhammad Waheed Akhtar; Muhammad Farooq Sabar; Nadia Sajid; Nawaf Al Anazi; Aamer Aleem; Zafar Iqbal
Journal:  J Cancer       Date:  2018-10-21       Impact factor: 4.207

5.  Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

Authors:  Renata Mendes de Freitas; Carlos Magno da Costa Maranduba
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.